UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2015
Commission File Number: 001-31368
SANOFI
(Translation of registrant’s name into English)
54, rue La Boétie, 75008 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
|
Form 20-F x |
Form 40-F o |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
|
Yes o |
No x |
If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
In June 2015, Sanofi issued the statements attached hereto as Exhibit 99.1 to 99.3 which are incorporated herein by reference.
Exhibit List
|
Exhibit No. |
|
Description |
|
|
|
|
|
Exhibit 99.1 |
|
Press release dated June 9, 2015: FDA Advisory Committee Recommends Approval of Sanofi and Regeneron’s Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia |
|
|
|
|
|
Exhibit 99.2 |
|
Press release dated June 8, 2015: Sanofi’s Lyxumia® (lixisenatide) Demonstrated Cardiovascular Safety in People with Type 2 Diabetes and High CV Risk |
|
|
|
|
|
Exhibit 99.3 |
|
Press release dated June 6, 2015: Sanofi Announces Positive Results for Toujeo® in Phase III Study Extension in Japanese People with Uncontrolled Diabetes |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Dated: June 17, 2015 |
|
SANOFI | |
|
|
|
| |
|
|
|
| |
|
|
By |
/S/ John Felitti | |
|
|
|
Name: |
John Felitti |
|
|
|
Title: |
Associate Vice President, |
|
|
|
Corporate Law, Financial & Securities Law | |
Exhibit Index
|
Exhibit No. |
|
Description |
|
|
|
|
|
Exhibit 99.1 |
|
Press release dated June 9, 2015: FDA Advisory Committee Recommends Approval of Sanofi and Regeneron’s Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia |
|
|
|
|
|
Exhibit 99.2 |
|
Press release dated June 8, 2015: Sanofi’s Lyxumia® (lixisenatide) Demonstrated Cardiovascular Safety in People with Type 2 Diabetes and High CV Risk |
|
|
|
|
|
Exhibit 99.3 |
|
Press release dated June 6, 2015: Sanofi Announces Positive Results for Toujeo® in Phase III Study Extension in Japanese People with Uncontrolled Diabetes |